BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Sign Up to like & getrecommendations! Published in 2017 at "CNS oncology"
DOI: 10.2217/cns-2016-0034
Abstract: We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial… read more here.
Keywords: braf v600e; mutant papillary; braf; combination braf ... See more keywords